Skip to main
INCY

Incyte (INCY) Stock Forecast & Price Target

Incyte (INCY) Analyst Ratings

Based on 20 analyst ratings
Buy
Strong Buy 25%
Buy 20%
Hold 55%
Sell 0%
Strong Sell 0%

Bulls say

Incyte is making smart strategic moves to enhance its drug delivery methods, with its ENHANZE technology through Halozyme, creating a subQ alternative for its leading drug Jakafi, increasing convenience for patients while maintaining its market share. The recent CMS settlement and EU label approval for Opzelura also add to Incyte's stronghold in the dermatology market, making it a credible growth bridge through Jakafi LOE. Overall, with a strong pipeline and promising clinical trial results, Incyte is well-positioned for future success in the small-molecule drug market.

Bears say

Incyte is currently overvalued, with a DCF-based valuation resulting in a lower 12-month price objective of $140 per share. Risks for the company include slower market uptake, delays in approvals for late-stage candidates, failure to generate positive data for ongoing programs, and potential long-term equity dilution risk. This could be due to factors such as lower-than-expected growth from current assets and unexpected successes from the pipeline.

Incyte (INCY) has been analyzed by 20 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 20% recommend Buy, 55% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Incyte and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Incyte (INCY) Forecast

Analysts have given Incyte (INCY) a Buy based on their latest research and market trends.

According to 20 analysts, Incyte (INCY) has a Buy consensus rating as of Aug 4, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $117.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $117.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Incyte (INCY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.